Nexium sales

 According to the search results, Nexium (esomeprazole), a proton pump inhibitor manufactured by AstraZeneca, lost its global patents in May 2014. The key points regarding Nexium's sales are:

• Nexium recorded global sales of $3.87 billion in 2013, including $2.12 billion in the U.S. alone.5
• Nexium was approved in the U.S. in April 2005.5
• AstraZeneca was able to extend Nexium's patent protection through various means, allowing it to maintain blockbuster sales even after the original patent expired.134
• Teva received FDA approval to market a generic version of Nexium in 2015, but the approval was later revoked.3

So in summary, Nexium's peak annual sales in the U.S. during its patent life were around $2.12 billion in 2013.5 AstraZeneca was able to maintain high sales of Nexium for several years after the original patent expired through various patent extension strategies.

https://www.perplexity.ai/search/the-drug-Prilosec-HUJ7iruhREmXIioK_Jx1IA

DO PHARMACISTS BUY BAYER?
Brand preimum

https://scholar.harvard.edu/files/shapiro/files/generics.pdf

Bronnenberg et al 2015

. In a detailed case study of headache remedies we find that more informed or expert consumers are less likely to pay extra to buy national brands, with pharmacists choosing them over store brands only 9 percent of the time, compared to 26 percent of the time for the average consumer.

https://www.perplexity.ai/search/the-drug-Prilosec-HUJ7iruhREmXIioK_Jx1IA

Based on the information provided in the search results, the key points regarding branded vs. generic aspirin sales are:

• According to the Harvard study in 1, a 100-tablet package of 325mg Bayer Aspirin costs $6.29, while a 100-tablet package of 325mg CVS store-brand aspirin costs $1.99. This represents a three-fold price premium for the branded Bayer aspirin.
• The same study found that 25% of aspirin sales by volume (and 60% by expenditure) are for national-brand products like Bayer, even though the store-brand alternatives are identical in dosage, directions, and active ingredient.1
• This suggests that around 1 in 4 consumers (or 25%) are willing to pay the higher price for the branded Bayer aspirin, while the remaining 3 in 4 consumers (or 75%) opt for the less expensive store-brand alternative.1

So in summary, the search results indicate that as of a 2015 publication, approximately 25% of aspirin consumers were buying the more expensive branded Bayer aspirin, while 75% were purchasing the identical but lower-cost generic/store-brand aspirin. The branded aspirin was priced around 3-4 times higher than the generic version.

60% could be cut to 20% of total savings of 40% nearly half.